Navigation Links
Calithera Biosciences Closes $40 Million in Series A Financing
Date:7/8/2010

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million.  Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round.  The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.  

"Promoting apoptosis in cancer cells is a validated approach to the treatment of cancer, as many oncology drugs on the market today are known to kill tumor cells by activating apoptotic pathways, albeit through indirect means," said Susan Molineaux, Ph.D., co-founder and Chief Executive Officer of Calithera.  "By targeting caspases directly, we hope to develop agents that have broad utility across many types of cancer, with greater specificity than current treatments and the potential to overcome chemoresistance."

Calithera's technology was developed by and licensed from the laboratory of co-founder James Wells, Ph.D., chair of the Department of Pharmaceutical Chemistry in the University of California, San Francisco School of Pharmacy.  Dr. Wells's laboratory has successfully identified several novel compounds that selectively activate procaspases and trigger apoptosis in cancer cells.  Proceeds from the financing will be used to advance one or more caspase activators through preclinical development and into Phase 1 clinical trials in cancer patients.  In parallel, the company will ex
'/>"/>

SOURCE Calithera Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. YM BioSciences raises US$3.2 million in support of JAK 1/2 program
7. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
8. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
9. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
10. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
11. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) provider ... provider of clinical research and data management services to ... its CRO Partnership Program, Clinovo expands ClinCapture , ... , “We have found Clinovo’s ClinCapture to exceed our ... is both user friendly and easy to deploy. The ...
(Date:11/26/2014)... 25, 2014 Miles Holder, formerly of ... Graphel Carbon Products team as Sales/Marketing Manager. Mr. Holder ... customer service for the graphite industry. , “We are ... team,” stated Dave Trinkley, VP of Market and Product ... of experience in the graphite industry, along with his ...
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation ... sur le marché européen au salon Hi Europe ... Amsterdam ). Curcumine la plus ... technologie amorphe (non-cristalline) à des ingrédients approuvés par ... un pigment jaune présent dans la racine de ...
(Date:11/24/2014)... , Nov. 24, 2014  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, today announced it has ... the U.S. Food and Drug Administration (FDA), which brings ... to seven, with eighteen submissions now pending at the ... and CEO of the Company, commented, "Our team here ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3IGI Laboratories, Inc. Announces ANDA Submission 2
... Calif., June 2, 2011 Providing a medical explanation for ... scientists from Brazil pursuing a study that started in Dr. ... a new gene regulator called MicroRNA 29 that keeps hearts ... to get to the molecular basis of why exercise is ...
... Tiny electrodes have been coated with a drug-loaded polymer ... detecting a number of neurological symptoms, such as those ... In a study published today, 2 June ... , researchers have developed a novel technology to precisely ...
... Lu, associate professor of materials science and engineering ... recipient of the Friedrich Wilhelm Bessel Research Award ... This award is for scholars, internationally renowned in ... 18 years ago and who are expected to ...
Cached Biology Technology:Scientists Discover Gene Regulator That Helps Hearts Through Exercise 2New technology could inspire brain implant for detecting and treating seizures 2Virginia Tech's Kathy Lu receives Humboldt Foundation research award 2
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
(Date:11/6/2014)... Fla. -- A groundbreaking paper from a team of ... understanding of how plants could adapt to and survive ... research, published in the latest issue of the journal ... chromatin (the complex of DNA and proteins) is organized ... so that some genes are turned on and others ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2
... Organisms living on small islands are particularly threatened ... assess these threats. A team of German and British ... of endangered reptiles and amphibians of the Comoro archipelago ... results to point out which species are most threatened ...
... -- Traditionally addressed through hand-weeding and/or herbicide application, controlling ... production. Increased labor costs have made hand-weeding prohibitive as ... may be effective and less expensive, non-target herbicide loss ... the environment. To address the economic and environmental impact ...
... Ariz. -- Associate Professor Paul Blowers of the University ... the 2011 Arizona Professor of the Year, recognized for ... the Advancement of Teaching and the Council for Advancement ... center announced the award on Nov. 17 in Washington, ...
Cached Biology News:Satellite images help species conservation 2Biodegradable mulches successfully control weeds in container-grown arborvitae 2Arizona Engineering associate professor earns national recognition 2
Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: